These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36834774)

  • 1. Calcium Handling in Inherited Cardiac Diseases: A Focus on Catecholaminergic Polymorphic Ventricular Tachycardia and Hypertrophic Cardiomyopathy.
    Zaffran S; Kraoua L; Jaouadi H
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Ca
    Keefe JA; Moore OM; Ho KS; Wehrens XHT
    Arch Toxicol; 2023 Jan; 97(1):73-92. PubMed ID: 36214829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
    Katz G; Arad M; Eldar M
    Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation.
    Chen B; Guo A; Gao Z; Wei S; Xie YP; Chen SR; Anderson ME; Song LS
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):841-9. PubMed ID: 22722659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium Signaling and Cardiac Arrhythmias.
    Landstrom AP; Dobrev D; Wehrens XHT
    Circ Res; 2017 Jun; 120(12):1969-1993. PubMed ID: 28596175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia.
    Herron TJ; Milstein ML; Anumonwo J; Priori SG; Jalife J
    Heart Rhythm; 2010 Aug; 7(8):1122-8. PubMed ID: 20538074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ryanodine receptor sensitivity governs the stability and synchrony of local calcium release during cardiac excitation-contraction coupling.
    Wescott AP; Jafri MS; Lederer WJ; Williams GS
    J Mol Cell Cardiol; 2016 Mar; 92():82-92. PubMed ID: 26827896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
    Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
    Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    Wleklinski MJ; Kannankeril PJ; Knollmann BC
    J Physiol; 2020 Jul; 598(14):2817-2834. PubMed ID: 32115705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
    Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.
    Suetomi T; Yano M; Uchinoumi H; Fukuda M; Hino A; Ono M; Xu X; Tateishi H; Okuda S; Doi M; Kobayashi S; Ikeda Y; Yamamoto T; Ikemoto N; Matsuzaki M
    Circulation; 2011 Aug; 124(6):682-94. PubMed ID: 21768539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Neco P; Torrente AG; Mesirca P; Zorio E; Liu N; Priori SG; Napolitano C; Richard S; Benitah JP; Mangoni ME; Gómez AM
    Circulation; 2012 Jul; 126(4):392-401. PubMed ID: 22711277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoplasmic Reticulum Ca
    Du Y; Demillard LJ; Ren J
    Biochem Pharmacol; 2022 Jun; 200():115059. PubMed ID: 35490731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.